News

Breast Macrodissect AI accurately identifies ductal carcinoma in situ (DCIS) and excludes this non-invasive region from invasive tumor analysis. Demonstrating the algorithm’s ability to differentiate between clinically relevant tissue architecture and improving molecular testing in breast cancer.

Indica Labs Sets New Standard for Molecular Testing in Breast Cancer with Expansion of AI Macrodissection Portfolio

Clinical, HALO AP, HALO Clinical AI, HALO Macrodissect Solutions, News, Press Releases / , , , ,

Albuquerque, NM, February 10, 2025 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced the expansion of its macrodissection portfolio with the launch of Breast Macrodissect AI . The suite now includes advanced algorithms for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and breast cancer, with prostate cancer planned for release in early 2026.

Indica Labs Sets New Standard for Molecular Testing in Breast Cancer with Expansion of AI Macrodissection Portfolio Read More »

Looking Back: Reviewing 2025 at Indica Labs

Blogs, Breast IHC AI, Cloud Services, CRC Macrodissect AI, HALO, HALO AI, HALO AI Apps, HALO AP, HALO AP Dx, HALO Clinical AI, HALO Link, Lung Macrodissect AI, News, Pharma Services, SlideQC BF / , , , , , , , , , ,

As we reach the end of 2025, the Indica Labs team extends our sincere thanks to the customers and collaborators who helped make this year one of remarkable innovation, growth, and scientific achievement.

Looking Back: Reviewing 2025 at Indica Labs Read More »

The rapid global adoption of HALO AP® prompted immediate localization of the platform in Chinese, Danish, Dutch, American and British English, Finnish, French, German, Greek, Italian, Norwegian, Japanese, Portuguese, Russian, Spanish, Slovakian, and Swedish. Shown here are all 17 languages represented as each country's flags.

Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets

Breast IHC AI, HALO AP, HALO AP Dx, HALO Clinical AI, HALO Macrodissect Solutions, Lung Macrodissect AI, News, Press Releases / , , , , , , , ,

Albuquerque, NM, December 17, 2025 – Indica Labs, the global leader in AI-powered digital pathology, announced today that clinical revenue growth rate for HALO AP® is up 260% since 2023 and recurring revenue for 2025 shows a 200% increase year-over-year, reinforcing its position as a market leader in digital pathology diagnostics.

Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets Read More »

Advancing Neuroscience Research with HALO® and HALO AI

Area Quantification, Area Quantification FL, Axon Quantification, Blogs, FISH, FISH-IF, HALO, HALO AI, HALO Modules, High Dimensional Analysis, Highplex FL, ISH, ISH-IHC, Microglial Activation, Microglial Activation FL, News, Object Colocalization, Object Colocalization FL, Spatial Analysis / , , , , , , , , , , , , , , , ,

As scientists work to continue unraveling the structural, cellular, and molecular complexities of the brain and its diseases, the characteristics of this unique tissue pose significant challenges to traditional histological analysis.

Advancing Neuroscience Research with HALO® and HALO AI Read More »

Announcing HALO® Muscle Fiber BF and Muscle Fiber FL Modules Supporting AI-Powered Segmentation and Interactive Markups

Blogs, HALO, HALO Modules, Muscle Fiber BF module, Muscle Fiber FL module, News / , , ,

We’re excited to announce the launch of the newly updated Muscle Fiber BF and Muscle Fiber FL modules supporting AI nuclear segmentation, AI membrane segmentation, interactive markups, and new output metrics..

Announcing HALO® Muscle Fiber BF and Muscle Fiber FL Modules Supporting AI-Powered Segmentation and Interactive Markups Read More »

Indica Labs, HALO AP Dx, FDA 510(k)-cleared digital pathology platform displayed with the Aperio GT 450 DX Scanner for in vitro diagnostic use.

Indica Labs Receives FDA Clearance for Enterprise Digital Pathology Platform with Industry Leading DICOM-Compatible Aperio Scanner from Leica Biosystems

Clinical, HALO AP, HALO AP Dx, News, Press Releases / , ,

ALBUQUERQUE, NM, and VISTA, CA, December 3, 2025 – Indica Labs, the global leader of AI-powered digital pathology, and Leica Biosystems, a global leader in anatomic and digital pathology solutions, announced today that the Food and Drug Administration (FDA) has issued a 510(k) clearance for the enterprise digital pathology platform HALO AP Dx in conjunction with Leica Biosystems Aperio GT 450 DX Scanner for in-vitro diagnostic use.

Indica Labs Receives FDA Clearance for Enterprise Digital Pathology Platform with Industry Leading DICOM-Compatible Aperio Scanner from Leica Biosystems Read More »

Free Demo
Free Demo
Scroll to Top